Netupitant-Palonosetron FDC Market Figures and Analytical Insights, 2 Netupitant Healthcare | Page 5

Netupitant-Palonosetron FDC Market Opportunities, Demand and
Forecasts, 2017 - 2027
Fixes dose combination for the treatment of Chemotherapy-induced Nausea and Vomiting is said to be
effective and is expected to overcome the side-effects of chemotherapy. Netupitant – Palonosetron FDC
is approved by U.S Food and Drug Administration for the prevention of acute nausea and vomiting during
cancer treatment process. The therapeutic drug is the combination of two drugs, namely Netupitant and
Palonosetron. Palonosetron was approved by FDA in 2008. It is a serotonin subtype 3 (5-HT3) receptor
antagonis for the prevention of acute nausea and vomiting. Netupitant is a (NK1) receptor antagonist
given after the start of chemotherapy. Antiemetics are less effective in controlling nausea and vomiting
because the intensity is high than actual vomiting. Proper antiemetics can prevent CINV in about 60%-
70% of patients.
Request For Report Sample@ http://www.futuremarketinsights.com/toc/rep-gb-3096
Netupitant-Palonosetron FDC Market: Drivers and Restrains
According to Word Health Organization, it is estimated that by 2030, about 23.6 million new cases of
cancer will prevail worldwide. Netupitant-Palonosetron Fixed Dose Combination is expected to fulfill
unmet needs of the chemotherapy-induced nausea and vomiting therapeutics market. The fixed dose
combination studies has revealed positive results in clinical phase trials. The demand of this drug for
better treatment option by physician and patients will drive the market. Intense research and
development in cancer therapeutics, the rise in the incidence of cancer cases, increased preference
toward chemotherapy for the treatment of cancer and the use of chemotherapy in combination with
other cancer treatment are anticipated to fuel the growth of Netupitant-Palonosetron FDC Market.
©2015 Future Market Insights, All Rights Reserved
5